Shots: The P-IIb VISION-DMD study involves assessing the efficacy & safety of vamorolone (2&6 mg/kg/day) vs PBO and prednisone (0.75 mg/kg/day) in 121 ambulant boys aged 4 to <7 years with DMD for 48 wks. The study met its 1EP i.e improvement in TTSTAND velocity, following the 1st period @24 wks. The 2 EPs include […]Read More
Shots: The last patient is out from the P-IIb part of its multinational P-IIb/III study of NP-120 for the COVID-19 has now completed treatment with 2wk follow up The company reports positive interim results for the P-IIb part of it P-IIb/III Ifenprodil COVID-19 study and expecting the final data set by end of Feb 2021 […]Read More
Shots: The P-IIb study will evaluate three dose levels of ION449 (once a month, SC) vs PBO and will enroll ~108 patients aged 18-75yrs., who have LDL-C levels b/w 70-190 mg/dL and are receiving moderate/ high-intensity statin therapy The P-I study results demonstrated dose-dependent mean reductions in circulating plasma PCSK9 and LDL-C levels of >90% […]Read More
Shots: The P-IIb study involves assessing SAR442168 vs PBO in patients with recurring MS. The one group of patients received 4 doses of SAR442168 @12wks., then crossed over to PBO @4wks. while the other group of patients received PBO @4wks. before crossing over to SAR442168 The P-IIb study resulted in meeting its 1EPs i.e. reduction […]Read More
Shots: The P-IIb study involves assessing of M72/AS01E vs PBO in 3,573 adults in a ratio (1:1) to prevent Mycobacterium tuberculosis infection from developing pulmonary tuberculosis disease in tuberculosis-endemic regions across 11 sites in Kenya, South Africa and Zambia The P-IIb study results demonstrated a reduction in the incidence of pulmonary TB in HIV-negative adults […]Read More
Shots: Janssen to pay ~$25M milestone payments to Arrowhead with the onset of trial and has begun the dosing of patients in REEF-1(NCT03982186) P-IIB study involving assessing of JNJ-3989, JNJ-6379, NA, and/or PBO in 450 patients with chronic hepatitis B virus infection for 48 wks., evaluating its safety and efficacy Additionally, in Oct 2018 Arrowhead […]Read More
Shots: The termination is based on results from P-IIb study, assessing Novexatin vs PBO, which was unable to meet a main goal of study under FDA guidelines with no superiority over PBO In 2013, Taro entered into license and co-development agreement with NovaBiotics for its novel antifungal peptide Novexatin Novexatin is a fast-acting topical drug […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
